Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20093617 | 0.79 | HDAC3 (0.41) | LMNANPSR1ALDH1A1CHRM2GAA | |
| SCHEMBL5332387 | 0.74 | LMNA (0.39) | CA2LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL354774 | 0.74 | CHRM2 (0.68) | CA2ALDH1A1CHRM2POLB | |
| SCHEMBL5503364 | 0.73 | CA2 (0.40) | CA2LMNAALDH1A1CHRM2PKM | |
| SCHEMBL20093616 | 0.72 | KMT2A (0.36) | LMNAALDH1A1PKMSMN1; SMN2MAPT | |
| SCHEMBL917453 | 0.71 | CA2 (0.46) | CA2LMNAPKM | |
| SCHEMBL5332672 | 0.71 | CA2 (0.40) | CA2ALOX5 | |
| SCHEMBL6009871 | 0.70 | CA1 (0.44) | CA2ALDH1A1GAAMAPK1TP53 | |
| SCHEMBL353848 | 0.70 | SLC2A1 (0.38) | CA2ALDH1A1 | |
| SCHEMBL918439 | 0.70 | KMT2A (0.38) | CA2LMNAALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | CA2 2710/4885LMNA 478/4885NPSR1 2461/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CA2 1085/4885LMNA 71/4885NPSR1 2840/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | CA2 1405/4885LMNA 89/4885NPSR1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.